Skip to content
TrialScanner

NCT02234986

A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma

Phase 2CompletedCASIFLead

Registry record

Lead sponsor
CASI pharmaceuticals, Inc.
Conditions
Advanced Adult Hepatocellular Carcinoma; Advanced Fibrolamellar Carcinoma
Primary completion
Jun 30, 2018Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02234986 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT02234986: A Multi-center, Open-label... | TrialScanner